Market Watch
Search documents
New York Times files copyright-infringement suit against Microsoft and OpenAI
Market Watch· 2023-12-27 09:36
The New York Times on Wednesday filed a copyright lawsuit against Microsoft and ChatGPT creator OpenAI in a legal action expected to shape the debate over generative-artificial-intelligence technologies. In a suit that may have a wide impact on the future of the news-publishing business, the New York Times alleges that technology companies including Microsoft Corp. MSFT, -0.17% and OpenAI used its content without authorization to create AI products. Microsoft launched an AI-powered chatbot, Copilot, earl ...
Tesla has ‘good mojo' in China as the EV maker enters 2024, analyst says
Market Watch· 2023-12-27 08:48
The Chinese market is a standout for Tesla Inc. providing the electric-vehicle maker with “good mojo into 2024,” according to Wedbush analyst Dan Ives. “With the last week of December now here we believe Tesla is tracking slightly ahead of the 480k delivery unit bogey for 4Q based on strong data out of the key China region that gives us incremental confidence in our bullish call into 2024,” wrote Ives, a longtime Tesla bull, in a note to clients. “We have seen some clear price stabilization globally wit ...
Williams to pay $2 billion to buy natural gas storage assets from Hartree Partners
Market Watch· 2023-12-27 08:22
Williams Companies WMB, -0.06% announced Wednesday an agreement to buy a portfolio of natural gas storage assets for $1.95 billion from an affiliate of Hartree Partners L.P. The deal includes six underground storage facilities in Louisiana and Mississippi and 230 miles of gas transmission pipeline. The deal is expected to close in January 2024. “These assets better position Williams’ natural gas storage operations to serve Gulf Coast LNG demand and growing electrification loads from data centers along the ...
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Market Watch· 2023-12-27 07:50
Fusion Pharmaceuticals Inc.’s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday. Bristol Meyers Squibb Co. BMY, -1.61% announced plans Tuesday to acquire Rayze Bio Inc. RYZB, +100.85% for $4.1 billion. Meanwhile Eli Lilly & Co.’s LLY, ...
Plug Power installs first hydrogen-producing system at an Amazon fulfillment center, but stock pulls back
Market Watch· 2023-12-27 07:14
Plug Power Inc. PLUG, +5.75% said Wednesday that it completed the first installation of an electrolyzer system at a Amazon.com Inc. AMZN, -0.01% fulfillment center. Plug Power’s stock fell 1.3% in premarket trading, putting it on track to snap a three-day win streak in which it ran up 14.9%. The proton exchange membrane electrolyzer produces hydrogen to fuel more than 225 hydrogen fuel-cell powered forklift trucks at the site, in Aurora, Colo. Plug Power said it has worked with Amazon to deploy more than 1 ...
2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.
Market Watch· 2023-12-27 06:56
The S&P 500 index has three days left this year to try for a fresh record high, which in theory, shouldn’t be so hard with a Santa Rally all but teed up. The index is 0.45% away from surpassing the 4796.56 high hit Jan. 3, 2022, but lethargy lurks for Wednesday. With the index sitting on a respectable 24% gain after last year’s 19% rout, it seems logical investors would want to ride out the rest of the year on the sidelines.Read: S&P 500 is moving toward record territory. Here’s what stock-market investors ...
Tesla reportedly will build revamped Model Y in Shanghai in 2024
Market Watch· 2023-12-26 21:03
Tesla Inc. is preparing to launch an updated version of its popular Model Y SUV at its plant in Shanghai, Bloomberg News reported late Tuesday. According to Bloomberg, the revamped Model Y will feature significant interior and exterior changes, and is expected to reach mass production as soon as mid-2024. The Shanghai facility will pause production for about a week after the new year to upgrade its production capabilities, Bloomberg reported, citing sources familiar with the matter. The plant will need a ...
Intel's stock on pace for biggest daily percentage gain in two months, buoyed by Israel deal
Market Watch· 2023-12-26 14:35
Shares of Intel Corp. rose 4.7% Tuesday, lifted by the announcement of a $25 billion investment in Israel.Intel’s stock INTC, +4.67% is on pace for its biggest daily percentage gain since Nov. 16, when it rose 6.8%. The S&P 500 index SPX is up 0.4% Tuesday.The chip giant’s investment comes after Intel secured $3.2 billion in incentives from Israel, according to Bloomberg. The Times of Israel reports that Intel’s $25 billion investment will support a chip-manufacturing plant in the city of Kiryat Gat that wi ...
Apple's stock heads for 4th straight loss, as it appeals Watch ban
Market Watch· 2023-12-26 14:23
Shares of Apple Inc. AAPL, -0.31% slipped 0.3% in afternoon trading, to put them on track for a fourth straight decline, after The Wall Street Journal’s report that the technology behemoth appealed a federal trade agency’s ban of two Apple Watch models because of patent violations. The stock’s decline comes despite the 0.5% rally in the tech-heavy Nasdaq 100 NDX, +0.51% and the Dow Jones Industrial Average’s DJIA, +0.48% 158-point, or 0.4% gain. The stock has lost 2.0% last week, while the Nasdaq 100 tacke ...
Amgen's NDA for Lumakras cancer treatment resulted in complete response letter
Market Watch· 2023-12-26 09:26
Amgen Inc. AMGN, -0.67% said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a “complete response letter” from the U.S. Food and Drug Administration. A CRL means the application will not be approved in its current form. The biotechnology company said the FDA also issued a new postmarketing requirement of an additional study to support full approval, to be completed no later than February 2028. The NDA for Lumakras was based on result ...